09 July 2021 : Clinical Research
Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China
Chunmei Ye12BCEF, Weiwei Chen3EF, Qi Gao12B, Yanxia Chen4B, Xiaolu Song5B, Sujie Zheng2C, Jinlin Liu2AEG*DOI: 10.12659/MSM.930241
Med Sci Monit 2021; 27:e930241
Table 3 Clinical characteristics of multiple myeloma patients with and without secondary immunodeficiency.
| IgG <5 g/L (n=45) | IgG ≥5 g/L (n=103) | |
|---|---|---|
| Sex | ||
| Male | 34 (75.56) | 63 (61.17) |
| Female | 11 (24.44) | 40 (38.83) |
| Age | ||
| ≤65 years | 23 (51.11) | 51 (49.51) |
| >65 years | 22 (48.89) | 52 (50.49) |
| Subtype | ||
| IgA, λ light chain | 15 (33.33) | 11 (10.68) |
| IgA, κ light chain | 12 (26.67) | 3 (2.91) |
| IgD, λ light chain | 5 (11.11) | 4 (3.88) |
| IgG, λ light chain | 1 (2.22) | 35 (33.98) |
| IgG, κ light chain | 0 (0.00) | 25 (24.27) |
| λ light chain | 6 (13.33) | 6 (5.83) |
| κ light chain | 4 (8.89) | 8 (7.77) |
| IgA | 0 (0.00) | 1 (0.97) |
| IgG | 0 (0.00) | 1 (0.97) |
| IgG, IgA, λ light chain | 0 (0.00) | 1 (0.97) |
| Unknown | 2 (4.44) | 8 (7.77) |
| All the data were presented with no. (%). | ||